Histamine is a biogenic amine implicated in various biological and pathological processes. Convenient cellular models are needed to screen and develop new antihistamine agents. This report aimed to characterize the response of neurons differentiated from mouse P19 embryonal carcinoma cells to histamine treatment, and to investigate the modulation of this response by antihistamine drugs, vegetal diamine oxidase, and catalase. The exposure of P19 neurons to histamine reduced cell viability to 65% maximally. This effect involves specific histamine receptors, since it was prevented by treatment with desloratadine and cimetidine, respectively, H-1 and H-2 antagonists, but not by the H-3 antagonist ciproxifan. RT-PCR analysis showed that P19 neurons express H-1 and H-2 receptors, and the H-3 receptor, although it seemed not involved in the histamine effect on these cells. The H-4 receptor was not expressed. H-1 and H-2 antagonists as well as vegetal diamine oxidase diminished the intracellular Ca2+ mobilization triggered by histamine. The treatment with vegetal diamine oxidase or catalase protected against mortality and a significant reduction of H2O2 level, generated from the cells under the histamine action, was found upon treatments with desloratadine, cimetidine, vegetal diamine oxidase, or catalase. Overall, the results indicate the expression of functional histamine receptors and open the possibility of using P19 neurons as model system to study the roles of histamine and related drugs in neuronal pathogenesis. This model is less expensive to operate and can be easily implemented by current laboratories of analysis and by Contract Research Organizations.
P19-derived neuronal cells express H1, H2, and H3 histamine receptors: a biopharmaceutical approach to evaluate antihistamine agents / Perez, Mariela Gomez; Tanasie, Georgiana; Neree, Armelle Tchoumi; Suarez, Narjara Gonzalez; Lafortune, Clara; Paquin, Joanne; Marcocci, Lucia; Pietrangeli, Paola; Annabi, Borhane; Mateescu, Mircea Alexandru. - In: AMINO ACIDS. - ISSN 0939-4451. - (2023). [10.1007/s00726-023-03273-6]
P19-derived neuronal cells express H1, H2, and H3 histamine receptors: a biopharmaceutical approach to evaluate antihistamine agents
Marcocci, Lucia;Pietrangeli, Paola;
2023
Abstract
Histamine is a biogenic amine implicated in various biological and pathological processes. Convenient cellular models are needed to screen and develop new antihistamine agents. This report aimed to characterize the response of neurons differentiated from mouse P19 embryonal carcinoma cells to histamine treatment, and to investigate the modulation of this response by antihistamine drugs, vegetal diamine oxidase, and catalase. The exposure of P19 neurons to histamine reduced cell viability to 65% maximally. This effect involves specific histamine receptors, since it was prevented by treatment with desloratadine and cimetidine, respectively, H-1 and H-2 antagonists, but not by the H-3 antagonist ciproxifan. RT-PCR analysis showed that P19 neurons express H-1 and H-2 receptors, and the H-3 receptor, although it seemed not involved in the histamine effect on these cells. The H-4 receptor was not expressed. H-1 and H-2 antagonists as well as vegetal diamine oxidase diminished the intracellular Ca2+ mobilization triggered by histamine. The treatment with vegetal diamine oxidase or catalase protected against mortality and a significant reduction of H2O2 level, generated from the cells under the histamine action, was found upon treatments with desloratadine, cimetidine, vegetal diamine oxidase, or catalase. Overall, the results indicate the expression of functional histamine receptors and open the possibility of using P19 neurons as model system to study the roles of histamine and related drugs in neuronal pathogenesis. This model is less expensive to operate and can be easily implemented by current laboratories of analysis and by Contract Research Organizations.File | Dimensione | Formato | |
---|---|---|---|
Perez_P19-neuronal_2023.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Creative commons
Dimensione
1.43 MB
Formato
Adobe PDF
|
1.43 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.